Literature DB >> 8893948

Neonatal meningitis due to Moraxella catarrhalis and review of the literature.

A Daoud1, F Abuekteish, H Masaadeh.   

Abstract

Moraxella catarrhalis has been reported with increasing frequency to be the aetiological agent of serious systemic infection in both children and adults. The first case of neonatal meningitis due to this organism is described herein. The fatal outcome and causes of failure of response to antimicrobial therapy are also discussed. A brief review of the literature describing the disease entities with which M. catarrhalis has been associated is presented.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8893948     DOI： 10.1080/02724936.1996.11747826

Source DB:  PubMed          Journal:  Ann Trop Paediatr        ISSN： 0272-4936


  11 in total

1.  Characterization of a novel porin protein from Moraxella catarrhalis and identification of an immunodominant surface loop.

Authors:  Donna M Easton; Adam Smith; Sara Gomez Gallego; A Ruth Foxwell; Allan W Cripps; Jennelle M Kyd
Journal:  J Bacteriol       Date:  2005-09       Impact factor: 3.490

2.  Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

Review 3.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

4.  Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins.

Authors:  W G Hu; J Chen; J F Battey; X X Gu
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

5.  The transferrin binding protein B of Moraxella catarrhalis elicits bactericidal antibodies and is a potential vaccine antigen.

Authors:  L E Myers; Y P Yang; R P Du; Q Wang; R E Harkness; A B Schryvers; M H Klein; S M Loosmore
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 6.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

7.  The rise and spread of a new pathogen: seroresistant Moraxella catarrhalis.

Authors:  Thierry Wirth; Giovanna Morelli; Barica Kusecek; Alex van Belkum; Cindy van der Schee; Axel Meyer; Mark Achtman
Journal:  Genome Res       Date:  2007-09-25       Impact factor: 9.043

8.  Moraxella catarrhalis M35 is a general porin that is important for growth under nutrient-limiting conditions and in the nasopharynges of mice.

Authors:  Donna M Easton; Elke Maier; Roland Benz; A Ruth Foxwell; Allan W Cripps; Jennelle M Kyd
Journal:  J Bacteriol       Date:  2008-10-17       Impact factor: 3.490

9.  Galactose residues on the lipooligosaccharide of Moraxella catarrhalis 26404 form the epitope recognized by the bactericidal antiserum from conjugate vaccination.

Authors:  Shengqing Yu; Hang Xie; Anup Datta; Natasha Naidu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2008-06-16       Impact factor: 3.441

10.  Mucosal immunization with the Moraxella Catarrhalis porin m35 induces enhanced bacterial clearance from the lung: a possible role for opsonophagocytosis.

Authors:  Donna M Easton; Allan W Cripps; A Ruth Foxwell; Jennelle M Kyd
Journal:  Front Immunol       Date:  2011-05-16       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.